3 Global Pharmaceutical Company, IT and Engineering Services Company and Abrasives and Ceramics Maker Stocks With a Strong Future Roadmap: Lupin, LTM and Grindwell Norton
- November 11, 2026
- Posted by: Ankit Jaiswal
- Category: Best Stocks
Lupin, LTM and Grindwell Norton: ROE of 16.4% to 23.8% and FY22 to FY26 revenue CAGR of 11.3% to 15.0%. Prices as of 10 Nov 2026.
Quick Answer
The three pharma, IT services and abrasive stocks to watch are Lupin, LTM and Grindwell Norton. Their return on equity ranges from 16.4% to 23.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 11.3% to 15.0%. Lupin leads on both return on equity at 23.8% and revenue growth at 15.0% a year. Prices are based on the 10 November 2026 close, and this article is educational, not investment advice.
Pharma, IT services and abrasive stocks offer a focused view of a sector where demand keeps widening. Lupin, LTM and Grindwell Norton cover a global pharmaceutical company, an IT and engineering services company and an abrasives and ceramics maker.
This list covers three pharma, IT services and abrasive stocks with complete current figures: Lupin, LTM and Grindwell Norton. Every figure comes from the latest reported financials and the 10 November 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Pharma, IT Services and Abrasive Stocks?
Pharma, IT services and abrasive stocks are listed companies that develop and sell generic and branded medicines in India and abroad, provide IT, cloud and engineering services to global clients, and make grinding wheels, coated abrasives and industrial ceramics. Their earnings depend on prescription demand, client technology budgets and factory output.
Pharma, IT Services and Abrasive Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Lupin | 2,025 | 89,343 | 16.1 | 36.0 | 23.8 | 0.29 |
| LTM | 4,318.2 | 120,479 | 23.2 | 17.6 | 20.2 | 0.09 |
| Grindwell Norton | 1,961.7 | 20,188 | 46.1 | 44.4 | 16.4 | 0.02 |
On valuation, Lupin trades at a P/E below the industry P/E, while LTM and Grindwell Norton trade above it, which reflects the growth the market already expects. Readers comparing pharma, IT services and abrasive stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do Pharma, IT Services and Abrasive Stocks Have a Strong Roadmap in India?
Pharma, IT services and abrasive stocks have a strong roadmap in India because steady global demand for medicines, wider enterprise adoption of digital services and rising manufacturing activity keep widening the market for these companies.
- Pharma. Generic and branded medicines reach more markets.
- IT services. Large clients consolidate vendors for digital work.
- Abrasives. Factories need grinding and finishing products.
Why Lupin Features Among These Pharma, IT Services and Abrasive Stocks
Among the pharma, IT services and abrasive stocks on this list, Lupin is a Mumbai-headquartered global pharmaceutical company with a presence in branded generics in India, complex generics and specialty products in the United States, and active ingredients, with strength in respiratory, cardiovascular, anti-diabetic and anti-infective therapies.
Revenue rose from Rs 16,616 crore in FY22 to Rs 29,039 crore in FY26, a compound annual growth rate of 15.0%. Net profit grew from Rs 1,936 crore in FY24 to Rs 5,355 crore in FY26, which works out to a compound annual growth rate of 66.3%.
In the June 2026 quarter, revenue grew 32.5% year on year to Rs 8,407 crore, while net profit rose 16.0% to Rs 1,417 crore. The company has a return on equity of 23.8%, a debt to equity ratio of 0.29 and a market capitalisation of Rs 89,343 crore. The stock trades at a P/E of 16.1, below the industry P/E of 36.0.
Roadmap: The company is building its pipeline of complex generics, inhalation products and biosimilars, and is widening its specialty portfolio in the United States. Its large Indian branded business and a presence in over 100 markets spread revenue across regions and therapies.
What to watch: Track key launches in the United States, especially in inhalation and complex injectables, and the growth of the India branded business.
Why LTM Features Among These Pharma, IT Services and Abrasive Stocks
Among the medicine maker, digital engineering and grinding wheel shares on this list, LTM, formerly LTIMindtree, is a Mumbai-based global technology consulting and digital solutions company that serves banking, insurance, manufacturing, healthcare and other industries.
Revenue rose from Rs 26,874 crore in FY22 to Rs 43,402 crore in FY26, a compound annual growth rate of 12.7%. Net profit grew from Rs 3,950 crore in FY22 to Rs 4,983 crore in FY26, which works out to a compound annual growth rate of 6.0%.
The company has a return on equity of 20.2%, a debt to equity ratio of 0.09 and a market capitalisation of Rs 120,479 crore. The stock trades at a P/E of 23.2, above the industry P/E of 17.6.
Roadmap: The company is focused on cloud, data and artificial intelligence projects and on winning larger transformation deals from existing clients. Its link with the Larsen and Toubro group helps it reach large enterprise customers.
What to watch: Track deal wins, client additions and utilisation levels.
Why Grindwell Norton Features Among These Pharma, IT Services and Abrasive Stocks
Among the three companies on this list, Grindwell Norton, a Saint-Gobain group company, makes abrasives, ceramics and plastics products, including grinding wheels, coated abrasives and silicon carbide.
The company has a return on equity of 16.4%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 20,188 crore. The stock trades at a P/E of 46.1, above the industry P/E of 44.4.
Revenue rose from Rs 2,066 crore in FY22 to Rs 3,168 crore in FY26, a compound annual growth rate of 11.3%. Net profit grew from Rs 295 crore in FY22 to Rs 417 crore in FY26, which works out to a compound annual growth rate of 9.0%. In the June 2026 quarter, revenue grew 13.8% year on year to Rs 828 crore, while net profit rose 22.1% to Rs 115 crore.
Roadmap: Demand from automobiles, steel, infrastructure and general manufacturing supports its core abrasives range, while ceramics and plastics offer higher-value niches. The group’s technology support and a debt-free balance sheet allow it to add capacity at its own pace.
What to watch: Keep tabs on industrial activity and input costs for raw materials such as silicon carbide.
Lupin vs LTM vs Grindwell Norton on Key Financials
The table below sets the three pharma, IT services and abrasive stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Lupin | 16,616 | 29,039 | 15.0% | 5,355 | 18.4% |
| LTM | 26,874 | 43,402 | 12.7% | 4,983 | 11.5% |
| Grindwell Norton | 2,066 | 3,168 | 11.3% | 417 | 13.2% |
Lupin posts the highest return on equity in this group at 23.8%. LTM has the largest FY26 revenue at Rs 43,402 crore, and Lupin shows the fastest revenue growth with a 15.0% compound annual rate. A useful habit with pharma, IT services and abrasive stocks is to check each new quarterly result against the capacity plans the company described earlier.
Key Risks to Check Before Investing in Pharma, IT Services and Abrasive Stocks
Every theme carries risks that deserve a check before any decision. For these pharma, IT services and abrasive stocks, the main points are: Long-term medicine maker, digital engineering and grinding wheel shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Pricing pressure. Generic prices can change by market.
- Client spending. Technology budgets can vary with global conditions.
- Commodity inputs. Metal, energy and raw material prices can move margins.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter pharma, IT services and abrasive stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Pharma, IT Services and Abrasive Stocks
Pharma, IT services and abrasive stocks reward patient research into demand, execution and financial strength. Lupin, LTM and Grindwell Norton each have a clear plan to grow. Based on the 10 November 2026 close, Lupin trades at Rs 2,025, LTM at Rs 4,318.2 and Grindwell Norton at Rs 1,961.7. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these pharma, IT services and abrasive stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track pharma, IT services and abrasive stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are pharma, IT services and abrasive stocks?
Ans. Pharma, IT services and abrasive stocks are listed companies that develop and sell generic and branded medicines in India and abroad, provide IT, cloud and engineering services to global clients, and make grinding wheels, coated abrasives and industrial ceramics. Their earnings depend on prescription demand, client technology budgets and factory output. This list looks at three of them, Lupin, LTM and Grindwell Norton, using reported FY22 to FY26 financials and the 10 November 2026 closing prices.
Which pharma, IT services and abrasive stocks are covered in this list?
Ans. This list covers Lupin, LTM and Grindwell Norton. Based on the 10 November 2026 close, Lupin traded at Rs 2,025, LTM at Rs 4,318.2 and Grindwell Norton at Rs 1,961.7. Their return on equity ranges from 16.4% to 23.8%, and their revenue compound annual growth from FY22 to FY26 ranges from 11.3% to 15.0%.
Why do pharma, IT services and abrasive stocks have a strong future roadmap in India?
Ans. Pharma, IT services and abrasive stocks have a strong roadmap in India because steady global demand for medicines, wider enterprise adoption of digital services and rising manufacturing activity keep widening the market for these companies. The main drivers are as follows. Pharma. Generic and branded medicines reach more markets. IT services. Large clients consolidate vendors for digital work. Abrasives. Factories need grinding and finishing products. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Lupin performed financially?
Ans. Revenue rose from Rs 16,616 crore in FY22 to Rs 29,039 crore in FY26, a compound annual growth rate of 15.0%. Net profit grew from Rs 1,936 crore in FY24 to Rs 5,355 crore in FY26, which works out to a compound annual growth rate of 66.3%. In the June 2026 quarter, revenue grew 32.5% year on year to Rs 8,407 crore, while net profit rose 16.0% to Rs 1,417 crore. The company has a return on equity of 23.8%, a debt to equity ratio of 0.29 and a market capitalisation of Rs 89,343 crore. The stock trades at a P/E of 16.1, below the industry P/E of 36.0. Looking ahead, the company is building its pipeline of complex generics, inhalation products and biosimilars, and is widening its specialty portfolio in the United States. Its large Indian branded business and a presence in over 100 markets spread revenue across regions and therapies.
How has LTM performed financially?
Ans. Revenue rose from Rs 26,874 crore in FY22 to Rs 43,402 crore in FY26, a compound annual growth rate of 12.7%. Net profit grew from Rs 3,950 crore in FY22 to Rs 4,983 crore in FY26, which works out to a compound annual growth rate of 6.0%. The company has a return on equity of 20.2%, a debt to equity ratio of 0.09 and a market capitalisation of Rs 120,479 crore. The stock trades at a P/E of 23.2, above the industry P/E of 17.6. Looking ahead, the company is focused on cloud, data and artificial intelligence projects and on winning larger transformation deals from existing clients. Its link with the Larsen and Toubro group helps it reach large enterprise customers.
How has Grindwell Norton performed financially?
Ans. Revenue rose from Rs 2,066 crore in FY22 to Rs 3,168 crore in FY26, a compound annual growth rate of 11.3%. Net profit grew from Rs 295 crore in FY22 to Rs 417 crore in FY26, which works out to a compound annual growth rate of 9.0%. In the June 2026 quarter, revenue grew 13.8% year on year to Rs 828 crore, while net profit rose 22.1% to Rs 115 crore. The company has a return on equity of 16.4%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 20,188 crore. The stock trades at a P/E of 46.1, above the industry P/E of 44.4. Looking ahead, demand from automobiles, steel, infrastructure and general manufacturing supports its core abrasives range, while ceramics and plastics offer higher-value niches. The group’s technology support and a debt-free balance sheet allow it to add capacity at its own pace.
What risks should investors check before buying pharma, IT services and abrasive stocks?
Ans. Investors should check a few risks before buying pharma, IT services and abrasive stocks. Pricing pressure. Generic prices can change by market. Client spending. Technology budgets can vary with global conditions. Commodity inputs. Metal, energy and raw material prices can move margins. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of pharma, IT services and abrasive stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 10 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
